HomeCompareCPAMF vs ABBV

CPAMF vs ABBV: Dividend Comparison 2026

CPAMF yields 4.93% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CPAMF wins by $352.3K in total portfolio value· pulled ahead in Year 3
10 years
CPAMF
CPAMF
● Live price
4.93%
Share price
$1.84
Annual div
$0.09
5Y div CAGR
46.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$454.6K
Annual income
$242,410.38
Full CPAMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CPAMF vs ABBV

📍 CPAMF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPAMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPAMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPAMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPAMF
Annual income on $10K today (after 15% tax)
$419.47/yr
After 10yr DRIP, annual income (after tax)
$206,048.82/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CPAMF beats the other by $184,992.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPAMF + ABBV for your $10,000?

CPAMF: 50%ABBV: 50%
100% ABBV50/50100% CPAMF
Portfolio after 10yr
$278.5K
Annual income
$133,591.07/yr
Blended yield
47.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CPAMF
No analyst data
Altman Z
1.4
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPAMF buys
0
ABBV buys
0
No recent congressional trades found for CPAMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPAMFABBV
Forward yield4.93%3.06%
Annual dividend / share$0.09$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR46.5%40.6%
Portfolio after 10y$454.6K$102.3K
Annual income after 10y$242,410.38$24,771.77
Total dividends collected$410.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CPAMF vs ABBV ($10,000, DRIP)

YearCPAMF PortfolioCPAMF Income/yrABBV PortfolioABBV Income/yrGap
1$11,423$722.97$11,550$430.00$127.00ABBV
2$13,353$1,130.71$13,472$627.96$119.00ABBV
3← crossover$16,098$1,809.74$15,906$926.08+$192.00CPAMF
4$20,212$2,987.08$19,071$1,382.55+$1.1KCPAMF
5$26,761$5,134.96$23,302$2,095.81+$3.5KCPAMF
6$37,944$9,308.90$29,150$3,237.93+$8.8KCPAMF
7$58,671$18,070.98$37,536$5,121.41+$21.1KCPAMF
8$101,035$38,257.59$50,079$8,338.38+$51.0KCPAMF
9$198,311$90,203.44$69,753$14,065.80+$128.6KCPAMF
10$454,603$242,410.38$102,337$24,771.77+$352.3KCPAMF

CPAMF vs ABBV: Complete Analysis 2026

CPAMFStock

CapitaLand Integrated Commercial Trust (CICT) is the first and largest real estate investment trust (REIT) listed on Singapore Exchange Securities Trading Limited (SGX-ST) with a market capitalisation of S$14.0 billion as at 31 December 2020. It debuted on SGX-ST as CapitaLand Mall Trust in July 2002 and was renamed CICT in November 2020 following the merger with CapitaLand Commercial Trust. CICT owns and invests in quality income-producing assets primarily used for commercial (including retail and/or office) purpose, located predominantly in Singapore. As the largest proxy for Singapore commercial real estate, CICT's portfolio comprises 22 properties in Singapore and two in Frankfurt, Germany, with a total property value of S$22.3 billion as at 31 December 2020. CICT is managed by CapitaLand Integrated Commercial Trust Management Limited, which is a wholly owned subsidiary of Singapore-listed CapitaLand Limited, one of Asia's largest diversified real estate groups.

Full CPAMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CPAMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPAMF vs SCHDCPAMF vs JEPICPAMF vs OCPAMF vs KOCPAMF vs MAINCPAMF vs JNJCPAMF vs MRKCPAMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.